Published in J Gastroenterol on May 06, 2008
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One (2013) 1.06
Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol (2012) 0.94
Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol (2013) 0.92
Effect of dietary advanced glycation end products on mouse liver. PLoS One (2012) 0.89
Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol (2009) 0.88
Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro. Lab Invest (2012) 0.83
The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity. J Gastroenterol (2010) 0.81
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol (2014) 0.79
Inhibitory effects of Ecklonia cava extract on high glucose-induced hepatic stellate cell activation. Mar Drugs (2011) 0.79
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol (2015) 0.78
Role of receptor for advanced glycation end products (RAGE) in liver disease. Eur J Med Res (2015) 0.78
Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.75
Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci (2014) 0.75
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases. Diagnostics (Basel) (2016) 0.75
Advanced Glycation End Products Induce Obesity and Hepatosteatosis in CD-1 Wild-Type Mice. Biomed Res Int (2016) 0.75
Effects of the dihydrolipoyl histidinate zinc complex against carbon tetrachloride-induced hepatic fibrosis in rats. Surg Today (2014) 0.75
Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. Clin Exp Med (2012) 0.75
Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion. World J Gastroenterol (2017) 0.75
Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 12.80
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest (2003) 3.69
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr (2000) 2.88
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology (1999) 2.07
Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med (2003) 1.87
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys (2000) 1.74
Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem (1994) 1.57
Link between mitochondria and NADPH oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death. J Biol Chem (2006) 1.47
Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology (2005) 1.42
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation (1997) 1.38
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun (2002) 1.36
Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res (2007) 1.34
NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology (2005) 1.29
Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology (2001) 1.29
Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis (2000) 1.18
Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun (1995) 1.03
Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med (2001) 0.99
Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett (2002) 0.96
Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells. Lab Invest (1995) 0.95
TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses (2004) 0.94
Immunological detection of a novel advanced glycation end-product. Mol Med (2001) 0.92
Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol (2004) 0.89
Roles of the AGE-RAGE system in vascular injury in diabetes. Ann N Y Acad Sci (2000) 0.88
Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int (2004) 0.86
Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor kappaB and intracellular reactive oxygen species formation. Arch Biochem Biophys (2003) 0.85
Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts. Biochim Biophys Acta (2000) 0.85
Advanced glycosylation end products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells. Mol Cell Endocrinol (2002) 0.83
Kinetics of gene induction after FcepsilonRI ligation of atopic monocytes identified by suppression subtractive hybridization. J Immunol (2002) 0.77
Respiratory chain components involved in the glycerophosphate dehydrogenase-dependent ROS production by brown adipose tissue mitochondria. Biochim Biophys Acta (2007) 0.75
Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc (2006) 5.42
Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med (2002) 5.30
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis (2012) 3.91
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation (2003) 2.69
Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. Gastrointest Endosc (2007) 2.62
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem (2002) 2.23
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer (2010) 2.20
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic submucosal dissection. Gastrointest Endosc (2012) 2.12
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet (2011) 2.09
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet (2005) 2.08
Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc (2007) 2.04
Genetic polymorphisms and esophageal cancer risk. Int J Cancer (2007) 2.02
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging (2011) 2.00
A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet (2011) 1.96
Narrow-band imaging magnification predicts the histology and invasion depth of colorectal tumors. Gastrointest Endosc (2009) 1.92
Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet (2010) 1.90
Optical biopsy of GI lesions by reflectance-type laser-scanning confocal microscopy. Gastrointest Endosc (2007) 1.87
Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol (2002) 1.86
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut (2010) 1.85
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
G to A hypermutation of hepatitis B virus. Hepatology (2005) 1.83
Clinicopathologic features and endoscopic resection of early primary nonampullary duodenal carcinoma. J Clin Gastroenterol (2003) 1.76
Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment. World J Surg (2007) 1.73
Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci (2012) 1.72
Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells (2008) 1.72
Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol (2012) 1.72
Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol (2008) 1.71
Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. Int J Colorectal Dis (2014) 1.70
Improved visibility of lesions of the small intestine via capsule endoscopy with computed virtual chromoendoscopy. Gastrointest Endosc (2011) 1.67
Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique. Gastrointest Endosc (2005) 1.67
Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest (2009) 1.65
Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv (2011) 1.63
Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer (2003) 1.60
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol (2010) 1.56
Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol (2011) 1.54
CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. J Atheroscler Thromb (2015) 1.50
Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage. AJR Am J Roentgenol (2002) 1.48
Frequent somatic mutations of mitochondrial DNA in traditional serrated adenomas but not in sessile serrated adenomas of the colorectum. J Gastroenterol Hepatol (2011) 1.47
Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan: a retrospective multicenter analysis. J Infect Chemother (2012) 1.47
Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors. Dig Endosc (2012) 1.47
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J Gastroenterol Hepatol (2010) 1.46
Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology (2005) 1.46
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer (2002) 1.46
Poor oral health, that is, decreased frequency of tooth brushing, is associated with endothelial dysfunction. Circ J (2014) 1.46
Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter (2011) 1.43
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes (2006) 1.43
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology (2010) 1.42
Usefulness of EUS with double-balloon enteroscopy for diagnosis of small-bowel diseases. Gastrointest Endosc (2007) 1.42
Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci (2004) 1.41
A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology (2009) 1.39
Comparison of detectability of small-bowel lesions between capsule endoscopy and double-balloon endoscopy for patients with suspected small-bowel disease. Gastrointest Endosc (2009) 1.39
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial. J Gastroenterol Hepatol (2008) 1.39
Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens (2002) 1.39
Relationships between Causes of Fever of Unknown Origin and Inflammatory Markers: A Multicenter Collaborative Retrospective Study. Intern Med (2015) 1.38
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun (2002) 1.36
Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol (2003) 1.36
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Pat Cardiovasc Drug Discov (2006) 1.35
Outcome of endoscopic submucosal dissection for colorectal tumors accompanied by fibrosis. Scand J Gastroenterol (2010) 1.34
Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol (2012) 1.34
Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol (2007) 1.33
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol (2011) 1.32
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J (2002) 1.32
Evaluation of microvessels in colorectal tumors by narrow band imaging magnification. Gastrointest Endosc (2007) 1.32
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Defensive medicine practices among gastroenterologists in Japan. World J Gastroenterol (2006) 1.31
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol (2010) 1.31
Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res (2005) 1.31
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem (2006) 1.30
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol (2004) 1.29
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol (2003) 1.29
Tetrahydrobiopterin improves aging-related impairment of endothelium-dependent vasodilation through increase in nitric oxide production. Atherosclerosis (2005) 1.28
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem (2002) 1.27
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol (2012) 1.27
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism (2006) 1.26
Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications (2002) 1.26
Usefulness of endoscopic ultrasonography in determining the depth of invasion and indication for endoscopic treatment of early gastric cancer. J Clin Gastroenterol (2009) 1.26
Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J Lipid Res (2003) 1.24
Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet (2013) 1.24
Warning for unprincipled colorectal endoscopic submucosal dissection: accurate diagnosis and reasonable treatment strategy. Dig Endosc (2012) 1.24